Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.

Nicotinamide riboside supplementation safe but ineffective in obese, insulin-resistant men

03 Sep 2018

Dietary nicotinamide riboside (NR) supplementation in 2,000-mg doses daily over a 12-week period is safe, a recent study has shown. However, it does not improve insulin sensitivity and whole-body glucose metabolism in obese, insulin-resistant men.

NR supplementation failed to improve insulin sensitivity, endogenous glucose production, and glucose disposal and oxidation. NR supplementation also had no effect on resting energy expenditure, lipolysis, oxidation of lipids or body composition.

On the other hand, there were no serious adverse events caused by NR supplementation. Safety blood tests were also normal.

In this investigator-initiated randomized, placebo-controlled, double-blinded and parallel-group designed clinical trial, a total of 40 healthy, sedentary men (age range, 40–70 years) with a body mass index of >30 kg/m2 were randomly assigned to 12 weeks of NR (1,000 mg twice daily) or placebo.

The effects of NR supplementation on insulin sensitivity were determined by a hyperinsulinaemic euglycaemic clamp and substrate metabolism by indirect calorimetry and labeled substrates of tritiated glucose and palmitate.

Whole-body dual-energy X-ray absorptiometry and MRI scans were used to determine body composition and fat mass distribution. Finally, MR spectroscopy was used to obtain measurement of intrahepatic lipid content.

“Animal studies suggest a positive role for NR on insulin sensitivity and hepatic steatosis in models of obesity and type 2 diabetes,” the authors said. “NR, an NAD+ precursor, is a member of the vitamin B-3 family now available as an over-the-counter supplement.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.